Neurologique Foundation

PRISM: A Novel Research Tool to Assess the Prevalence of Pseudobulbar Affect Symptoms across Neurological Conditions

Benjamin Rix Brooks, David W. Crumpacker, Jonathan Fellus et al. · PLoS ONE · 2013 · 74 citations · Full text

Medicine, Neurology, Clinical Neuroscience +12

Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient- and physician-reported outcomes in relapsing multiple sclerosis: post hocanalyses of the EPOC trial

Jonathan Calkwood, Bruce Cree, Heidi Crayton et al. · BMC Neurology · 2014 · 37 citations · Full text

Pharmacy, Neurology, Pharmacotherapy +17

Gatifloxacin Ophthalmic Solution for Treatment of Bacterial Conjunctivitis: Safety, Efficacy and Patient Perspective

Clyde Schultz · Ophthalmology and Eye Diseases · 2012 · 24 citations · Full text

Medicine, Ophthalmology, Pharmacotherapy +17

PRISM: A Novel Tool to Prospectively Estimate the Prevalence of Pseudobulbar Affect Symptoms

David W. Crumpacker, Jonathan Fellus, Daniel Kantor et al. · American Journal of Geriatric Psychiatry · 2013 · 17 citations · Full text

Nursing, Dermatology, Clinical Epidemiology +11

First-dose effects of fingolimod after switching from injectable therapies in the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis

Bruce Hughes, Mark Cascione, Mark S. Freedman et al. · Multiple Sclerosis and Related Disorders · 2014 · 13 citations

Medicine, Neurology, Pharmacotherapy +11